By Dr. Kate Placzek, ZRT Laboratory
Premenstrual Dysphoric Disorder (PMDD) is a severe, cyclical condition that affects an estimated 3–8% of menstruating women. Unlike typical PMS, PMDD causes debilitating mood and physical symptoms in the week before menstruation — symptoms severe enough to interfere with work, relationships, and daily life. If you've been told your symptoms are "just PMS" but they feel far more intense, this guide explains what's really happening hormonally and what you can do about it.
Is PMDD Worse than PMS? Yes — Significantly.
PMS is common. PMDD is a different level entirely. While PMS involves manageable discomfort, PMDD is classified in the DSM-5 as a distinct diagnostic category — requiring at least 5 specific symptoms during most menstrual cycles, occurring in the luteal phase (the week before your period), and severe enough to cause functional impairment.
The distinction matters because PMDD requires a different approach to management — and often, a clearer picture of what your hormones are actually doing across your cycle. You can read more about the overlap between PMS and PMDD in our article on feeling awful at that time of the month.
What is PMDD?
PMDD is a luteal phase-specific syndrome on the severe end of the PMS spectrum. Approximately 3–8% of menstruating women experience the same constellation of symptoms as PMS but at a much higher intensity. The burden of PMDD is cyclical and predictable — a monthly detriment to quality of life for the patient and those around them.
PMDD is defined by having at least 5 symptoms in most menstrual cycles involving severe mood changes and physical symptoms. These must occur during the week before menstruation and improve shortly after the onset of menses.
How Does PMDD Occur? The Hormonal Mechanism
The etiology of PMDD is still being researched, but it is closely tied to hormonal shifts across the menstrual cycle — specifically in the luteal phase, when progesterone rises sharply after ovulation.
Women with PMDD typically feel well in the follicular phase (when progesterone is low) and feel significantly worse once ovulation occurs and progesterone begins to rise. This seems counterintuitive, since progesterone is generally regarded as a calming, anxiety-relieving hormone. The answer lies not in progesterone itself, but in how it is metabolised.
The Role of Progesterone Metabolism
The key player is allopregnanolone — a neuroactive steroid metabolite of progesterone. Allopregnanolone levels rise in tandem with progesterone across the luteal phase and, by targeting the GABA-A receptor, normally produce anxiolytic and sedative effects [2]. In women with PMDD, however, this same mechanism triggers negative mood states rather than calming ones.
If you suspect your progesterone or oestrogen levels may be contributing to cyclical symptoms, a comprehensive hormone profile can provide a baseline picture of your sex hormone levels — useful context before exploring cycle-specific testing.
The Inverted U-Shaped Effect
Research shows that PMDD symptoms can be relieved when ovarian hormones are suppressed altogether, or when allopregnanolone is pushed beyond physiological luteal levels. In other words, it is the normal luteal levels of progesterone-turned-allopregnanolone that are particularly triggering for women with PMDD.
Although allopregnanolone levels between PMDD and non-PMDD groups are not significantly different [4,5], what distinguishes individuals with PMDD is dysregulated GABA-A receptor organisation. Women with PMDD exhibit differences in GABA-A sub-unit structure and abnormal patterns of neural activation [7–9].
PMDD Therapeutic Management
Management of PMDD focuses on symptom control, with the goal of avoiding progesterone levels equivalent to normal physiological luteal levels. Evidence-based approaches include:
- Oral contraceptives — suppress ovarian steroids to bring relief from PMDD symptoms [10].
- SSRIs (Selective Serotonin Reuptake Inhibitors) — initiated at symptom onset and discontinued at menstruation. Their rapid action in PMDD may be explained by their ability to enhance allopregnanolone formation from progesterone [11].
- Progesterone supplementation — paradoxically, pushing allopregnanolone beyond peak luteal levels can reduce symptom severity [12,13].
- 5α-reductase inhibitors — prevent formation of allopregnanolone from progesterone, reducing core PMDD symptoms [4].
PMDD is cyclical — it leaves, and it returns. The goal is to make it manageable and to understand the hormonal patterns driving it.
Can Hormone Testing Help with PMDD?
Because PMDD is driven by hormonal fluctuations across the menstrual cycle — not just a single snapshot — standard one-time hormone tests often miss the picture. The most clinically useful approach is to track oestrogen and progesterone levels throughout the cycle, not just at one point.
Our 1 Month Hormone Test for Women – Menstrual Cycle Mapping is specifically designed for this. It tracks oestrogen and progesterone across the full cycle using dried urine samples collected at home, allowing you to see exactly when levels rise, peak, and fall — and whether the luteal phase pattern aligns with PMDD symptom timing.
For a broader hormonal picture that includes cortisol, DHEA, and other sex hormones alongside oestrogen and progesterone, the Female Saliva Hormone Profile provides a comprehensive baseline from a single saliva sample collected at home.
References
[1] Diagnostic and statistical manual of mental disorders DSM-5, fifth edition ed. 2013: APA, Washington, DC.
[2] Bixo, M., et al., Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder. J Neuroendocrinol, 2018. 30(2).
[3] Kanes, S., et al., Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet, 2017. 390(10093): p. 480-489.
[4] Martinez, P.E., et al., 5alpha-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder. Neuropsychopharmacology, 3/2016. 41(4): p. 1093-1102.
[5] Timby, E., et al., Women with premenstrual dysphoric disorder have altered sensitivity to allopregnanolone over the menstrual cycle compared to controls-a pilot study. Psychopharmacology (Berl.), 6/2016. 233(11): p. 2109-2117.
[6] Bixo, M., et al., Treatment of premenstrual dysphoric disorder with the GABAA receptor modulating steroid antagonist Sepranolone (UC1010)-A randomized controlled trial. Psychoneuroendocrinology, 6/2017. 80: p. 46-55.
[7] Rapkin, A.J., et al., Neuroimaging evidence of cerebellar involvement in premenstrual dysphoric disorder. Biol. Psychiatry, 2/15/2011. 69(4): p. 374-380.
[8] Berman, S.M., et al., Elevated gray matter volume of the emotional cerebellum in women with premenstrual dysphoric disorder. J Affect. Disord, 4/5/2013. 146(2): p. 266-271.
[9] Gingnell, M., et al., Social stimulation and corticolimbic reactivity in premenstrual dysphoric disorder: a preliminary study. Biol. Mood. Anxiety. Disord, 2014. 4(1): p. 3.
[10] Lopez, L.M., A.A. Kaptein, and F.M. Helmerhorst, Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev, 2012(2): p. CD006586.
[11] Hantsoo, L. and C.N. Epperson, Premenstrual Dysphoric Disorder: Epidemiology and Treatment. Curr. Psychiatry. Rep, 11/2015. 17(11): p. 87.
[12] Andreen, L., et al., Relationship between allopregnanolone and negative mood in postmenopausal women taking sequential hormone replacement therapy with vaginal progesterone. Psychoneuroendocrinology, 2/2005. 30(2): p. 212-224.
[13] Andreen, L., et al., Allopregnanolone concentration and mood--a bimodal association in postmenopausal women treated with oral progesterone. Psychopharmacology (Berl), 2006. 187(2): p. 209-221.